Sanara Medtech INC

MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million.

Sanara MedTech Inc. has mutually terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective immediately, as it shifts strategic focus.

Sanara MedTech reported 19% year-over-year revenue growth to $27.8 million and achieved GAAP net profitability for the first quarter of 2026.

Sanara MedTech Inc. announced robust fourth quarter and full year 2025 financial results, with net revenue exceeding $100 million, and reaffirmed its 2026 financial guidance.

Sanara MedTech Inc. announced preliminary Q4 and full-year 2025 financial results with significant revenue growth and introduced optimistic 2026 guidance.

Sanara MedTech Inc. will present its 2026 fiscal year priorities and strategy at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025.

Sanara MedTech Inc. announced a 19% increase in net revenue for Q1 2026, driven by strong performance in soft tissue repair products, and achieved net income from continuing operations.

Sanara MedTech reported significant revenue and gross profit growth in its continuing surgical operations for Q3 2025, alongside the strategic discontinuation and impairment of its Tissue Health Plus (THP) segment.

Sanara MedTech Inc. reports significant revenue growth in its surgical segment, alongside strategic investments in its new value-based wound care platform.

Sanara MedTech's Q1 2025 results show revenue growth driven by soft tissue repair products, alongside ongoing investments in Tissue Health Plus and strategic financial maneuvers.

Sanara MedTech Inc. saw a 35% increase in revenue year-over-year for the third quarter of 2024, driven by strong sales of soft tissue repair products.

Sanara MedTech Inc. reports a 28% increase in revenue for the second quarter of 2024, driven by strong sales of soft tissue repair products.

Sanara MedTech Inc. announces its annual results, highlighting a shift towards value-based wound care services and expansion in the surgical market.

Sanara MedTech Inc. reports a 42% increase in net revenue for 2023, driven by strategic acquisitions and market expansion, while also detailing a comprehensive value-based care strategy.

Sanara MedTech Inc. has entered into a definitive agreement to be acquired by MiMedx Group, Inc. in a cash and stock transaction valued at approximately $350 million.

Sanara MedTech announced an agreement to combine with MiMedx Group, creating a leading regenerative medicine company focused on surgical end markets.

Sanara MedTech announced an agreement to combine with MiMedx Group, creating a leading regenerative medicine company focused on surgical markets.

MiMedx Group Inc. announced its definitive agreement to acquire Sanara MedTech Inc. for $35 per share, a move expected to significantly expand its surgical business and create a leading regenerative medicine company.

MiMedx announced an agreement to acquire Sanara MedTech, aiming to bolster its regenerative medicine offerings and expand its surgical business.

MIMEDX and Sanara MedTech announced a definitive agreement for MIMEDX to acquire Sanara, aiming to create a larger regenerative medicine company in the surgical space.

Sanara MedTech Inc. has issued its 2026 Proxy Statement detailing the upcoming virtual Annual Meeting of Shareholders scheduled for June 4, 2026.

Sanara MedTech Inc. will hold its 2025 Annual Meeting of Shareholders virtually on May 22, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Sanara MedTech withdraws a proposal to increase the board size and elect a new director after the resignation of its CEO, Zachary B. Fleming.

Sanara MedTech's former CEO, Zach Fleming, has resigned, leading to the appointment of Ron Nixon as CEO and the withdrawal of a proposal for a ninth director at the upcoming annual meeting.

Sanara MedTech Inc. will hold its annual shareholder meeting virtually on June 12, 2024, to vote on director elections, amendments to the Certificate of Formation, approval of a Long-Term Incentive Plan, and ratification of the company's accounting firm.

Sanara MedTech Inc. will hold its annual shareholder meeting virtually on June 12, 2024, to vote on director elections, a certificate of formation amendment, a new incentive plan, and auditor ratification.

Sanara MedTech Inc. has filed a Schedule 13G amendment indicating zero beneficial ownership for reporting persons Tall Pines Capital, LLC and Stonebridge Wealth Management, LLC.

Baird Trust Company, Baird Financial Corporation, and Baird Financial Group, Inc. have collectively reported beneficial ownership of 21,075 shares of Sanara MedTech Inc. common stock.

Baird Trust Company and its affiliates have reported a beneficial ownership of 8.5% in Sanara MedTech Inc. common stock as of December 31, 2025.